{"entity":{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","aka":[],"tldr":"Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy.","summary":"Hervé Dombret is a haematologist at Hôpital Saint-Louis in Paris and a long-standing leader of the French ALFA and GRAALL leukaemia cooperative groups. He was first author of the 2015 Blood report of AZA-AML-001, the international phase 3 trial of azacitidine against conventional care regimens in older patients with newly diagnosed AML and more than 30 percent marrow blasts, which supported azacitidine's use in this population.","asOf":"2026-09-18","links":[],"tags":["leukaemia","trialist"],"related":[],"cancers":["aml-older-unfit","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-aza-aml-001-dombret-blood-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Hôpital Saint-Louis (AP-HP), Paris","institutionId":"aphp-nord-cancer-institute","specialisms":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dombret%5BAuthor%5D"}],"papers":[]},"route":"/people/herve-dombret/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"}],"institution":[{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/"}],"paper":[{"id":"paper-aza-aml-001-dombret-blood-2015","kind":"paper","name":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","route":"/key-papers/paper-aza-aml-001-dombret-blood-2015/"}]}}